Gadodiamide
Description
Type: small molecule
Groups: approved
Indication: For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
Accession Number: DB00225 ( APRD00990)
Description: Gadodiamide is a gadolinium based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan. [Wikipedia]
Structure:
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Omniscan | solution | 287 mg | intravenous | 25-03-1997 | Canada | |
Omniscan | injection | 287 mg/mL | intravenous | 19-04-2002 | US | |
Omniscan | injection | 287 mg/mL | intravenous | 29-07-2005 | US | |
Omniscan Liq IV 287mg/ml | liquid | 287 mg | intravenous | 31-12-1994 | 30-07-1997 | Canada |
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Omniscan | solution | 287 mg | intravenous | 25-03-1997 | Canada | |
Omniscan | injection | 287 mg/mL | intravenous | 19-04-2002 | US | |
Omniscan | injection | 287 mg/mL | intravenous | 29-07-2005 | US | |
Omniscan Liq IV 287mg/ml | liquid | 287 mg | intravenous | 31-12-1994 | 30-07-1997 | Canada |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
Brand Name | Ingredients |
---|---|
Omniscan | Gadodiamide |
Omniscan | Gadodiamide |
Omniscan | Gadodiamide |
Omniscan Liq IV 287mg/ml | Gadodiamide |
Brand Name | Ingredients |
---|---|
Omniscan | Gadodiamide |
Omniscan | Gadodiamide |
Omniscan | Gadodiamide |
Omniscan Liq IV 287mg/ml | Gadodiamide |
Categories
- No Category
Pharmacology
Pharmacodynamics: Not Available
Mechanism of action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, gadodiamide shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, gadodiamide primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadodiamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadodiamide in lesions such as neoplasms, abscesses, and subacute infarcts.
Absorption: Not Available
Volume of distribution:
- 200 ± 61 mL/kg
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Gadodiamide is eliminated primarily in the urine.
Half life: Two-compartment model with mean distribution and elimination half-lives (reported as mean ± SD) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively.
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
- Ge healthcare
Packagers:
- Amersham Health Inc.
- GE Healthcare Inc.
Dosage forms
Form | Route | Strength |
---|---|---|
Injection | intravenous | 287 mg/mL |
Solution | intravenous | 287 mg |
Liquid | intravenous | 287 mg |
Form | Route | Strength |
---|---|---|
Injection | intravenous | 287 mg/mL |
Solution | intravenous | 287 mg |
Liquid | intravenous | 287 mg |
Prices
Unit description | Cost | Unit |
---|---|---|
Omniscan 287 mg/ml bottle | $6.49 | ml |
Omniscan 287 mg/ml vial | $6.98 | ml |
Omniscan prefill plus syringe | $7.02 | ml |
Unit description | Cost | Unit |
---|---|---|
Omniscan 287 mg/ml bottle | $6.49 | ml |
Omniscan 287 mg/ml vial | $6.98 | ml |
Omniscan prefill plus syringe | $7.02 | ml |
Patents
Country | Patent Number | Approved | Expires (estimated) |
---|---|---|---|
1335819 | Canada | 1995-06-06 | 2012-06-06 |
5362475 | United States | 1994-11-08 | 2011-11-08 |
5560903 | United States | 1993-10-01 | 2013-10-01 |
Interactions
Drug | Interaction |
---|
Drug | Interaction |
---|
Food Interactions:
- Not Available
Taxonomy
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Alpha amino acids
- Carbonyl compounds
- Carboxylic acid salts
- Carboxylic acids
- Hydrocarbon derivatives
- Organic salts
- Organic zwitterions
- Secondary carboxylic acid amides
- Trialkylamines
- Tricarboxylic acids and derivatives
substituent:
- Aliphatic acyclic compound
- Alpha-amino acid
- Alpha-amino acid amide
- Amine
- Carbonyl group
- Carboxamide group
- Carboxylic acid
- Carboxylic acid amide
- Carboxylic acid salt
- Hydrocarbon derivative
- Organic salt
- Organic zwitterion
- Organonitrogen compound
- Organooxygen compound
- Secondary carboxylic acid amide
- Tertiary aliphatic amine
- Tertiary amine
- Tricarboxylic acid or derivatives
References
General Reference: Not Available
External Links:
Resource | Link |
---|---|
RxList | http://www.rxlist.com/cgi/generic3/omniscan.htm |
Resource | Link |
---|---|
RxList | http://www.rxlist.com/cgi/generic3/omniscan.htm |
ATC Codes:
- Array
AHFS Codes:
- 92:00.00
MSDS: Download